Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Cullman Clinical Trials (“CCT”) in its acquisition by Rovia Clinical Research, a portfolio company of Gauge Capital. CCT is a North Alabama-based, multi-specialty clinical research site with proven expertise in conducting clinical trials across several high-value therapeutic areas, including weight loss, vaccines, pulmonology, and neurology.
Provident’s deal team was led by Managing Director Michael Patton and Director Conor Duffey. Bradley Arant Boult Cummings served as legal counsel to CCT.
“Provident Healthcare Partners understood our business from the first conversation. I didn’t have to explain site-level economics, sponsor relationships, or why enrollment performance matters more than headcount; they already knew. That knowledge showed up in who they brought us. The partner we ended up with was the right fit for our team and our patients, not just the highest number in the room. I’d recommend them to any site owner thinking about a sale,” commented Alex Seligson, Managing Partner of CCT.
“Alex Seligson quickly grew Cullman Clinical Trials into one of the premier multi-specialty research sites in Alabama, an attractive clinical research market with limited private equity-backed competition. With particular strength in metabolic and pulmonology trials, CCT expands Rovia’s therapeutic reach while establishing a foothold in a growing clinical research market,” noted Conor Duffey of Provident.
About Cullman Clinical Trials
Headquartered in Cullman, Alabama, Cullman Clinical Trials is a multi-specialty clinical research site serving a large, underserved patient population across North and Central Alabama. Founded in 2017, CCT has built a strong reputation with sponsors and CROs across high-demand therapeutic areas, supported by an experienced investigator team and a track record of strong patient enrollment and retention. CCT’s commitment to operational excellence, from rapid study start-up to rigorous quality and compliance standards, has made it a preferred partner in its market. Visit cullmanclinicaltrials.com to learn more.
About Rovia Clinical Research
Rovia Clinical Research is a multi-specialty clinical research site network with 20+ years of research experience. It operates a hub-and-spoke model of freestanding sites and physician-embedded capabilities. Rovia operates 20 wholly owned sites across 8 states and serves under-represented regions such as Alabama, Mississippi, Louisiana and Missouri. Rovia’s core research focus includes endocrinology, obesity, cardiology, gastroenterology, neurology, psychiatry, ophthalmology, and infectious disease. Rovia has a proven history of enrolling patients with outstanding retention, rapid study start-up, and high-quality data. The network is a preferred partner to leading global pharmaceutical and biotechnology customers. Visit roviaclinical.com to learn more.
About Provident Healthcare Partners
Provident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation services for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including clinical research. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a multitude of investors such as private equity firms and strategic consolidators. For additional information, visit providenthp.com or follow Provident on LinkedIn.
Contact:
Provident Healthcare Partners
Conor Duffey
617-226-4294
cduffey@providenthp.com
